NCT06475235 2026-02-20
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Dana-Farber Cancer Institute
Phase 1 Recruiting
Clinical Trials
11 trialsNCT06208657 2026-01-28
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2 Recruiting
NCT00248534 2018-09-04
Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00109798 2017-09-19
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
The Methodist Hospital Research Institute
Phase NA Withdrawn
NCT02113007 2017-02-07
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00098774 2016-07-06
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01735747 2013-03-12
Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT00544284 2013-02-15
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
Phase 1 Completed
NCT00503594 2012-07-30
CNSLymphoma
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT00004106 2012-06-06
Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Northwestern University
Phase 2 Terminated
NCT00003567 2010-06-11
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated